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The Myf5 gene plays an important role in myogenic determination during mouse embryo development.
Multiple genomic regions of the Mrf4–Myf5 locus have been characterised as enhancer sequences
responsible for the complex spatiotemporal expression of the Myf5 gene at the onset of myogenesis.
These include an enhancer sequence, located at 111 kb upstream of the Myf5 transcription start site,
which is responsible of Myf5 activation in ventral somitic domains (Ribas et al., 2011. Dev. Biol. 355,
372–380). We show that the 111 kb-Myf5 enhancer also directs transgene expression in some limb
muscles, and is active at foetal as well as embryonic stages. We have carried out further characterisa-
tion of the regulation of this enhancer and show that the paired-box Pax3 transcription factor binds to
it in vitro as in vivo, and that Pax binding sites are essential for its activity. This requirement is
independent of the previously reported regulation by TEAD transcription factors. Six1/4 which, like
Pax3, are important upstream regulators of myogenesis, also bind in vivo to sites in the 111 kb-Myf5
enhancer and modulate its activity. The 111 kb-Myf5 enhancer therefore shares common functional
characteristics with another Myf5 regulatory sequence, the hypaxial and limb 145 bp-Myf5 enhancer,
both being directly regulated in vivo by Pax3 and Six1/4 proteins. However, in the case of the 111 kb-
Myf5 enhancer, Six has less effect and we conclude that Pax regulation plays a major role in controlling
this aspect of the Myf5 gene expression at the onset of myogenesis in the embryo.
& 2013 Elsevier Inc. All rights reserved.Introduction
The formation of skeletal muscle in vertebrates depends on
myogenic regulatory factors of the MyoD family. This subgroup of
basic-helix-loop-helix transcription factors is essential for entry
into the myogenic programme (MyoD, Myf5, Mrf4) and subse-
quent muscle differentiation (Myogenin, MyoD, Mrf4). Skeletal
muscles of the trunk and limbs derive from the paraxial meso-
derm of somites, where the dorsal domain, the dermomyotome, is
the source of myogenic progenitor cells, which delaminate from
this epithelium, to form the early myotome and trunk muscles, or
migrate to more distant sites before activating myogenic factors,
as in the limbs reviewed in Buckingham and Vincent (2009).
Anterior muscles, such as tongue muscles, arise from myogenic
cells present in the somite-derived hypoglossal chord, whereas
head muscles are formed from the mesodermal core of the ﬁrst
two branchial arches and from prechordal mesoderm reviewed in
Sambasivan et al. (2011). The gene encoding the myogenicll rights reserved.
ham).determination factor,Myf5 is activated at the onset of myogenesis
in the mouse embryo (Ott et al., 1991). It is in the same locus as
Mrf4, which plays an early role in myogenic determination
(Kassar-Duchossoy et al., 2004), but is subsequently activated in
differentiating muscle, unlike Myf5. The spatio-temporal control
of Myf5 transcription is complex and depends on a number of
distinct regulatory elements which extend over 140 kb 50 of the
gene (Carvajal et al., 2001; Hadchouel et al., 2000; Summerbell
et al., 2000). The ﬁrst site of expression, in the epaxial somite
from embryonic day E8.5, depends on an early epaxial enhancer
at 5.5 kb from Myf5 (Summerbell et al., 2000; Teboul et al.,
2002), which responds to Wnt and Sonic hedgehog (Shh) signal-
ling from the adjacent axial structures (Borello et al., 2006;
Gustafsson et al., 2002; Teboul et al., 2003) and is also targeted
by the transcription factor, Dmrt2, present in the dermomyotome
(Sato et al., 2010). Also in this proximal region between Mrf4 and
Myf5 genes, is a branchial arch element at 1 kb and a sequence that
activatesMyf5 in some cells in the neural tube (Carvajal et al., 2001).
An important regulatory region is located between 58/48 kb
(Hadchouel et al., 2000). This is composed of a number of elements,
including one which targets a sub-group of neurons in the central
nervous system, where post-transcriptional regulation prevents
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myogenic contribution of this region is due to an enhancer located
at 57.5 kb, where core activity in a 145 bp sequence is required for
Myf5 expression in the hypaxial somite from E10.5 and in the
developing limbs and hypoglossal chord. Molecular characterisation
of this sequence shows that it depends on the transcription factor
Pax3 (Bajard et al., 2006). Six1/4 factors affect its activity (Giordani
et al., 2007), which is also associated with another homeodomain
protein binding site (Buchberger et al., 2007). Pax3, and to a lesser
extent its orthologue Pax7, play a key role in myogenic progenitor
cells in the somite (Buckingham and Relaix, 2007), where Six1 and
Six4 are also important upstream regulators (Grifone et al., 2005).
Earlier activation of Myf5 in the hypaxial somite from E9.5, also
depends genetically on Pax3, but the regulatory element has not
been characterised (Bajard et al., 2006). A BAC transgenic approach
indicated that a region between 140 and 88 kb 50 of Myf5
contains this activity (Carvajal et al., 2001). As an indication of
potential function, DNA sequences that are highly conserved
between species have been identiﬁed within this region (Maak
et al., 2006). We have identiﬁed elements at 130, 116 and
111 kb 50 upstream of the mouse Myf5 gene and shown by
transgenic analysis that the sequence at 111 kb contains most of
the activity, targeting the hypaxial/central myotome from E9.5. This
is in accordance with the report of Ribas et al. (2011), who showed
that transcriptional activity of this sequence depends on a TEAD
factor binding site. Recently, the 111 kb sequence which interact
with Pax3/7 when they are overexpressed in a muscle cell line, has
been shown to be important in the activation of Myf5 in adult
quiescent satellite cells (Soleimani et al., 2012). We now show that
this 111 kb-Myf5 enhancer requires Pax3 for activity in the
embryo and that, like the 145 bp sequence at 57.5 kb, it also
contains Six1/4 binding sites. These results therefore place this
element within the Pax/Six regulatory pathway that leads to Myf5
activation and the onset of myogenesis. We conclude that both
TEAD and Pax3 binding are essential for 111 kb-Myf5 enhancer
activity.Materials and methods
Plasmid constructions and transgenesis
A 700 bp genomic fragment, corresponding to the 111 kb
region, was synthesized by PCR, with forward and reverse primers,
respectively containing XhoI and HindIII sites, and cloned into a PCR
2.1 TOPO vector (Invitrogen). After veriﬁcation of the sequence, the
XhoI-HindIII fragment was subcloned into a pbaMyf5-nLacZ vector
(Hadchouel et al., 2000) to generate the 111baMyf5nLacZ
construct. Similarly, 550 bp and 650 bp genomic fragments, corre-
sponding respectively to the conserved regions at 130 and
116 kb, were synthesised by PCR, using primers with either a
XhoI or a HindIII site, and cloned into a pGEMT-Easy vector
(Promega) and subsequently into the 111baMyf5nLacZ plasmid
in order to generate a 130/116/111 baMyf5nLacZ construct.
Mutagenesis of putative binding sites was performed by PCR
ampliﬁcation with the Expand High Fidelity PCR System (Roche),
using as a matrix a plasmid in which the 111 kb fragment had
been subcloned into a PCR 2.1 TOPO vector (Invitrogen) and two
primers, forward and reverse, complementary to their 50 extremities
as described in Daubas et al. (2009). Mutations were successively
made in Six binding sites (BS) and PaxBS using primers described in
Table S1. Mutation of the Nr2f2(COUPTF-II) site was carried out
using the QuickChange Multi Site-Directed Mutagenesis kit (Strata-
gene), following the instructions of the manufacturer with the
primers described in Table S1.Mouse lines, transgenesis and embryo analysis
The Pax3GFP/þ line has been previously described (Relaix et al.,
2005). Transgenic mice were obtained on a C57BL/6JxSJL genetic
background. Mice were maintained in the animal house of the
Pasteur institute, in accordance with the regulations of the French
Ministry of Agriculture, which also applied for sacriﬁce of mice
and embryo analysis. All transgenesis experiments were carried
out by injecting vectorless plasmid inserts and performed by the
Centre d’Inge´nierie Ge´ne´tique Murine of the Pasteur Institute
(F. Langa-Vives). Two 111baMyf5nLacZ mouse lines were devel-
oped. Heterozygous transgenic males were crossed with non-
transgenic females (C57BL/6JxSJL F1), and embryos were staged
taking E0.5 as the day of the vaginal plug. Otherwise functional
studies were carried out by transient transgenesis: embryos were
dated taking the day of reimplantation as E0.5. Somites were
counted for precise ageing of embryos. Embryos were screened
for transgene expression by X-Gal staining as described in
Tajbakhsh et al. (1996). Table S2 recapitulates the number of
transgenic embryos analysed for each transgene.
Immunoﬂuorescence
Immunoﬂuorescence was performed on X-Gal stained cryostat
sections of 20 mm of thickness using rabbit polyclonal anti-GFP
antibodies (Invitrogen) and anti-Rabbit IgG-Alexa 488 (Molecular
probes) as described in Daubas et al. (2000).
Electrophoretic mobility shift assays
The Pax3 expression plasmid was a gift from F. Relaix and
consisted of a full length mouse Pax3 cDNA cloned into a pcDNA3.1
vector (Invitrogen). Six1 and Six4 expression vectors were gifts from
P. Maire. Full length Six1 and Six4 cDNAs were cloned into the pCR3
CMV T7 expression vector (Invitrogen), as described in Spitz et al.
(1998). Nr2f2 (COUP-TFII) and HA-tagged Nr2f2(COUP-TFII) pcDNA3
expression vectors were gifts from T. Sato. Expression plasmid DNAs
were used to synthesise proteins in vitro with the TnT T7 Quick
Coupled Transcription/Translation System (Promega). Oligonucleo-
tides, containing respectively SixBS1, SixBS2, PaxBS1, PaxBS2 and
Nr2f2BS, are listed in Table S1. Oligonucleotide probes were 30 end-
labelled, using ATP g32P (PerkinElmer) and polynucleotide kinase
(Fermentas). EMSA binding assays were performed as described in
Bajard et al. (2006). Monoclonal anti-Pax3 (Developmental Studies
Hybridoma Bank, Iowa), polyclonal anti-Six1 and anti-Six4 (Sigma
Prestige antibodies) and monoclonal anti-HA (clone 3F10, Roche
Applied Science, Manheim, Germany) antibodies were used in EMSA
binding reactions for supershift assays. To study the binding of Pax3
and TEAD2, we used a TEAD-PBS1 oligonucleotide listed in Table S1.
Chromatin preparation and immunoprecipitation
The protocol used for chromatin immunoprecipitation (ChIP) was
derived from Navarro et al. (2010), with the following modiﬁcations:
the interlimb region was dissected from E10.5 mouse embryos in cold
phosphate buffered saline buffer (PBS, Invitrogen) and crosslinked in
1% formaldehyde (Thermo Scientiﬁc) for 5 min at room temperature,
with constant shaking. Tissues were dissociated a further 10 min in a
Dounce glass homogeniser. After 15min of cross-linking, the reaction
was quenched with 125mM glycine for 5 min at room temperature.
Cells were transfered to a cold tube, spun down for 3 min at 1000 g at
4 1C, and washed twice with cold PBS. Cell pellets were then re-
suspended in Triton buffer (0.25% TritonX100, 10 mM Tris–HCl pH8,
10 mM EDTA, 0.5 mM EGTA) freshly supplemented with protease
inhibitor cocktail (Complete, Roche). Nuclei were prepared in a
Dounce homogeniser. 10 ml of suspension were used to check nuclei
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for 5 min at 2000 rpm at 4 1C and re-suspended in 1.5 ml of TSE150
(0.1% SDS, 1% Triton, 2 mM EDTA, 20 mM Tris–HCl pH8, 150mM
NaCl) buffer, freshly supplemented with protease inhibitor cocktail.
Samples were sonicated at 4 1C in 15ml conical Falcon tubes using a
Bioruptor (Diagenode) for one cycle of 10 min, divided into 30 s on/
30 s off subcycles at low power, followed by 3 cycles at maximum
power. Chromatin was then transferred into 1.5 ml tubes and
centrifuged for 30 min at 14000 rpm at 4 1C. Soluble chromatin was
divided into aliquots and stored at 80 1C until use. 20 ml (corre-
sponding to the ) Input * fraction) were used for quantity and quality
control of the DNA. 20 ml of magnetic Protein G or A Dynabeads
(Dynal) were used for each ChIP. Beads were rinsed 3 times with cold
TSE150 buffer and 3 to 5 mg of antibodies were added, and left at 4 1C
overnight with rotative shaking. The following antibodies were used:
goat polyclonal anti-Pax3 antibodies (C-20, Santa Cruz Biotechnology,
Inc.), rabbit polyclonal anti-Six1 and Six4 (Sigma Prestige antibodies),
and rabbit polyclonal anti-histone H3 (tri methyl K4) (ChIP grade,
Abcam) and IgG from rabbit serum (Sigma) for controls. After anti-
body binding, beads were rinsed once with cold TSE150 and
sonicated chromatin was added in TSE150 overnight at 4 1C with
rotative shaking. Chromatin bound to Ab-beads was washed at room
temperature twice with TSE150 and then successively with TSE500
(0.1% SDS, 1% Triton, 2 mM EDTA, 20 mM Tris–HCl pH8, 500mM
NaCl), followed by washing buffer (10mM Tris–HCl pH8, 0.25M LiCl,
0.5% NP-40, 0.5% Na-deoxycholate, 1 mM EDTA) and TEN Buffer
(1 mM EDTA, 10 mM Tris–HCl pH8, 50 mM NaCl). Chromatin was
then de-crosslinked in elution buffer (10 mM Tris–HCl pH8, 1 mM
EDTA, 1% SDS) overnight, at 65 1C with vigorous shaking. Immuno-
precipitated chromatin was recovered from the beads, complemented
with glycogen (Mol. Biol. grade, Roche) and proteinase K to respective
ﬁnal concentrations of 0.02mg/ml and 0.4 mg/ml and incubated for
2 h at 37 1C. After addition of LiCl to a ﬁnal concentration of 440mM,
DNA was phenol/chloroform extracted, ethanol precipitated, washed
and resuspended in 60 ml of distillated RNAse/DNAse free water
(Gibco). Input DNA was prepared similarly from 20 ml of chromatin,
but resuspended in 100 ml of TE buffer and incubated at 37 1C for
30min with DNAse free-RNAse (Roche).
Real-time PCR analysis
All analyses were carried out in 96-well plates using a StepOne-
Plus PCR machine (Applied Biosystems) and the FastStart Universal
SYBR Green Master (Rox) (Roche). Reactions were performed in
duplicate or triplicate. 5 ml of DNA solution were used per reaction,
corresponding to 1 or 0.1 ml of immunoprecipitated DNA or Input
DNA, respectively. Standard curves of all primers were performed to
check for efﬁcient ampliﬁcation (above 90%). Melting curves were
also performed to verify production of single DNA species with each
primer pair. Primer sequences used for qPCR are listed in Table S1.
Relative levels of expression in each assay were obtained through the
DDCt method (Livak and Schmittgen, 2001). Results are expressed as
Fold Change in Occupancy, compared to negative control regions,
being equal to 2 DDCt.Results
Characterisation of novel Pax3, Six1/4 and Nr2f2(COUP-TFII) binding
sites in the 111 kb-Myf5 enhancer
We have selected three sequences in the 140/100 kb
region 50 upstream of the Myf5 transcription start site (Fig. S1A),
on the basis of their higher sequence conservation between
species and the presence of putative Pax3 consensus binding
sites. In order to test their activity, we subcloned these conservedregions into a pbaMyf5-nLacZ plasmid (Hadchouel et al., 2000),
where the branchial arch (ba) element present in the proximal
Myf5 promoter region provides a positive control, and tested
them in transient transgenic embryos at E10.5. A transgene,
130/116/111 baMyf5nLacZ, in which the three conserved
sequences are joined together, gives a similar somitic proﬁle of
b-galactosidase activity at E10.5 to that obtained with the
111 kb sequence alone (111baMyf5nLacZ, Fig. S1 B and Table
S2). We therefore conclude that transgene expression in the
central and hypaxial regions of more mature somites along
the rostro-caudal axis of the embryo is mainly directed by the
111 kb sequence (E3/ECR111). We focused our study on this
680 bp sequence that we named the 111 kb-Myf5 enhancer
(which functions in both orientations- result not shown). We
generated two 111baMyf5nLacZ stable mouse lines which gave
the same proﬁle of expression: the transgene begins to be
expressed in a few dispersed cells of cervical somites at E9.25
(20 somites- Fig. S2A) and its expression is stronger and extends
more caudally along the rostro-caudal axis of the embryo at E9.5
(25 somites), where b–galactosidase positive cells are restricted
to the central and hypaxial somite, with higher expression in
rostral and caudal edges of the somites (Fig. S2B and C0). At E10.5
(34 somites), the 111 kb-Myf5 enhancer drives strong transgene
expression in somites and sections at interlimb level show that
cells in the myotome and a few cells in the dermomyotome are b-
galactosidase positive. No labelled cells are detected in the
hypaxial lip of the dermomyotome (Fig. S2F). Later, at E14.0, both
transgenic lines show labelling in abdominal and intercostal
muscles and in some proximal muscles of the fore- and hind-
limbs (Fig. S2E). At earlier (E9.5) and later (E14.5) stages, the 130/
116/111baMyf5nLacZ transgene also shows similar expression to
that obtained with the 111baMyf5nLacZ construct (Fig. S3, Table
S2), consistent with our conclusion that the 111 kb sequence
directs most of the embryonic activity in this region.
We had previously demonstrated an essential role of Pax3 in the
activation of another regulatory sequence, namely the 145bp-Myf5
enhancer, located at 57.5 kb upstream from Myf5, which directs
expression in hypaxial somite derivates and notably in developing
limb muscles (Bajard et al., 2006). Six1/4 factors also reinforce
expression of this sequence (Giordani et al., 2007). In order to
examine whether these regulators also play a role in activation of
the 111 kb-Myf5 enhancer, we looked for putative Pax3 and Six1/4
(MEF-3) binding sequences. We found two putative Pax3 paired-
domain binding sites (PaxBS1-2, consensus 50CGTCACSST30 minus
strand) and two putative MEF-3 sites (SixBS1-2, consensus
50GWAANYNGA30), as well as two tandemly repeated binding sites
for Nr2f2 (COUP-TFII, consensus 50RGGTCA30), an orphan nuclear
receptor (Fig. 1A). These sites are conserved between different
vertebrate species (Fig. 1B), indicating their potential functional
importance. We performed electrophoretic mobility gel shifts assays
(EMSA) using short DNA probes containing each of these putative
binding sites, to test for their ability to bind in vitro synthesised
candidate proteins. Pax3 protein binds to PaxBS1 and 2 sites, with
similar afﬁnities (Fig. 2A and B). Speciﬁcity of this binding is
demonstrated by supershift experiments with anti-Pax3 antibodies
and competition with intact or mutated unlabelled probes (Fig. 2C).
Similarly, the two putative MEF-3 binding sites, SixBS1 and 2, bind
both Six1 and Six4 proteins. Supershifts are generated if anti-Six1 or
anti-Six4 antibodies are added and the speciﬁc binding is competed
with normal but not with mutated oligos (Fig. 2D). Finally, each of the
two tandemly repeated Nr2f2(COUP-TFII) binding sites strongly
interacts with wild-type or HA-tagged Nr2f2(COUP-TFII) proteins
and supershift experiments attest to the speciﬁcity of this binding
(Fig. 2E). As Dmrt2 binding sites have been characterised
in the early epaxial Myf5 enhancer element, and shown to play a
role in its activation (Sato et al., 2010), we looked for putative Dmrt2
Fig. 1. Identiﬁcation of novel binding sites within the 111 kb-Myf5 enhancer. (A) The single strand DNA sequence of the 111 kb-Myf5 enhancer (chromosome position
:NCBIM37: 10: 107033880:107034560). Putative binding sites (BS) for Six (MEF3), Pax3 and Nr2f2(COUP-TFII) are indicated as double stranded sequences , respectively in
green (SixBS1 and 2), red (PaxBS1 and 2) and blue (Nr2f2BS). PaxBS1 site is the Pax3/7 paired domain binding site described in Soleimani et al. (2012). Nucleotides written
above the sequence correspond to the mutations (m) of the different binding sites, used both in EMSA and transgenesis experiments. The boxed sequence (position 145–
151) corresponds to the M-CAT binding site for TEAD transcription factors (Ribas et al., 2011). Underlined sequences correspond to the oligonucleotide probes used in
EMSA experiments. (B) Sequence comparison of the putative Six, Pax3 and Nr2f2 binding sites between vertebrate species indicates a high degree of conservation.
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Dmrt2 binding sites were tested but did not show any Dmrt2 binding
in EMSA experiments (results not shown). A TEAD binding site,
CATTCCT, is located just 50 of the Pax3 paired domain binding site 1
(Fig. 1A). As this site has recently been shown to be essential for
111 kb-Myf5 enhancer function (Ribas et al., 2011), we tested
binding of both Pax3 and TEAD2 to the 111 kb enhancer. In EMSA
experiments, we observed that Pax3 and TEAD2 could bind to the
same DNA fragment to form a larger complex and that a mutation in
the TEAD binding site does not prevent Pax3 binding on the
neighbouring PBS1 site and that, vice versa, a mutation in the PBS1
binding site does not prevent TEAD2 binding at the TEAD site,
showing that the factors bind independently. Surprisingly, the bind-
ing of Pax3 alone was enhanced in the presence of TEAD2 without
complex formation, since the band size corresponds to Pax3 binding
(Fig. S4). In the presence of Pax3, TEAD2 binding is not affected. We
conclude that the adjacent TEAD and Pax3 sites bind these factors
independently and that there is not a signiﬁcant cooperative effect
between the proteins when binding to their sites.
Pax3 and Six1/4 proteins interact in vivo with the 111 kb-Myf5
enhancer and its activation is severely reduced in Pax3 GFP/GFP null
mutant embryos
We then examined the in vivo interaction of Pax3 and Six1 and 4
proteins at E10.5 with the 111 kb-Myf5 enhancer, using chromatin
immunoprecipitation (ChIP) followed by qPCR analysis. Chromatinwas prepared from the thoracic region of wild-type E10.5 embryos
in which 111 kb-Myf5 enhancer activity is robust. Using anti-Pax3
and anti-Six1 or anti-Six4 antibodies, we obtained a signiﬁcant fold
change in occupancy of the 111 kb enhancer by Pax3, Six1 and
Six4, compared with that of two negative control sequences in the
Myf5 gene locus at 257.5 and 55.2 kb (Fig. 3A), already used as
controls in ChIP studies with the same proteins (Bajard et al., 2006;
Giordani et al., 2007). Almost no change in occupancy is detected
between the 111 kb region and control regions if total IgGs from
non immune serum are used. This result indicates that the tran-
scription factors Pax3 and Six1/4 are bound in vivo to the 111 kb-
Myf5 enhancer, presumably at the sites characterised by EMSA
experiments.
In order to test genetically the importance of Pax3 as an
upstream regulator of this enhancer, we then examined the
expression of the 111baMyf5nLacZ transgene in Pax3GFP/þ and
Pax3GFP/GFP embryos (Relaix et al., 2005) at different stages
(Fig. 3B–J). By E10.5, in the absence of Pax3, there are somite
abnormalities, with foreshortening of the epaxial and the hypax-
ial domains of the dermomyotome (Tajbakhsh et al., 1997;
Tremblay et al., 1998), but the residual somite still present
expresses Pax3GFP and Myf5 (Bajard et al., 2006). On the Pax3GFP/
GFP null background, the somitic expression of the 111baMyf5n-
LacZ transgene is compromised at E11.25, compared to that of
Pax3GFP/þ embryos of the same litter (Fig. 3B and C). Remaining
expression in anterior somites may be due to activation by Pax7.
Where transgene expression is abolished, in interlimb somites,
Fig. 2. Pax3, Six1/4 and Nr2f2(COUP-TFII) proteins bind in vitro to the -111 kb-Myf5 enhancer. (A) In vitro synthesised Pax3 protein was added to a radioactively labelled
DNA probe containing either the PaxBS1 or the PaxBS2 binding sites. A bandshift (arrowhead) is observed when Pax3 is added (lanes 2, 3), compared to the control with
reticulocyte lysate alone (lane 1). Speciﬁcity of Pax3 binding at the PaxBS1 site (lane 4) is demonstrated by the supershift seen when anti-Pax3 antibodies are added (lane
5, asterisk). Pax3 binding is competed when a 50 and 200 molar excess of unlabelled Pax PBS1 probe is added (lanes 6, 7), but not competed after addition of a mutated
unlabelled oligonucleotide MutPaxPBS1(lanes 8, 9). The same experiment was carried out with the PaxBS2 probe and gave similar results (not shown). (B) Complexes
formed with a radioactively labelled SixBS1 probe and Six1 or Six4 proteins are shown in lanes 1 and 3 respectively (arrowheads) and are dissociated, with some indication
of a supershift, when anti-Six1 or, more clearly anti-Six4 antibodies are added (lanes 2, 4, asterisks). Binding of Six1 or Six4 is competed by a 200 molar excess of unlabelled
SixBS1 probe (lanes 5, 7 respectively),whereas it is not by a 200 molar excess of mutated unlabelled MutSixBS1probe (lanes 6, 8 for Six1 and Six4 respectively). Similar
results were obtained with SixBS2 (not shown). (C) Nr2f2 protein was added to a wild-type Nr2f2BS probe (lanes 1–4, left), Mut1Nr2f2BS probe with one (lanes 1–4,
middle), orMut2Nr2f2BS probe with two Nr2f2 mutated half sites (lanes 1–4, right). No binding is detected with crude reticulocyte lysate (lanes 1) and band shifts are
observed (arrowheads) with Nr2f2 (lanes 2, left and middle) or HA-tagged Nr2f2 (lanes 3, left and middle). The Nr2f2-HA complex is supershifted (asterisk) when anti-HA
antibodies are added (lanes 4, left and middle). No binding is observed when both Nr2f2 half binding sites are mutated (lanes 1–4, right).
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by GFP labelling on sections (Fig. 3D–G). At E13.0 (Fig. 3H–J), as at
E11.25, loss of transgene expression exceeds that expected for
loss of trunk muscles in Pax3GFP/GFP embryos (Relaix et al., 2005).
These observations suggest that Pax3 regulation of the 111 kb-
Myf5 enhancer plays an important role in vivo.
In vivo transgenic analysis of mutations of the putative binding sites:
a major role of Pax3 in 111 kb-Myf5 enhancer activity
In order to test directly the importance in vivo of the protein
binding sites characterised in vitro by EMSA experiments, we used
the transient transgenic technique to analyse mutations in the -
111baMyf5nLacZ transgene and their effects on enhancer activity
in embryos at E10.5. Mutations at both Six1/4 binding sites,
SixBS1/2, have only a moderate effect on transgene expression
at this stage, although the enhancer activity always appears
reduced when compared with the non-mutated construct
(Fig. 4A, B). Mutations of Pax3 binding sites PaxBS1/2, individually
or together, have a much more dramatic effect. Abolition of
binding capacity at PaxBS2 signiﬁcantly reduces enhancer activity
(Fig. 4C). In particular, this is clear in thoracic and caudal somites
where X-Gal labelling is seen only in their rostral and caudal
edges. The effect of mutating the other site, PaxBS1, is even more
pronounced, the enhancer being silent, except for a minor signal
in a few cervical somites (Fig. 4D). Mutation at both Pax3 binding
sites, PaxBS1 and 2, gives a similar result demonstrating the
major importance in vivo of Pax3 binding for activation of the111 kb-Myf5 enhancer (Fig. 4E). This result is also obtained
when both Six1/4 and Pax3 pairs of sites are mutated (Fig. 4F).
Transient transgenic analysis reveals that mutations of both Pax3
and Six1/4 binding sites also severely affect 111baMyf5nLacZ
transgene expression at later stages of embryonic development.
At E12.5 only faint nLacZ expression is detected in some cervical
somites and at E14.5, X-Gal staining in trunk and limb muscles is
no longer detectable (Fig.S5, Table S2). The Nr2f2(COUP-TFII)
binding site, identiﬁed in our EMSA experiments, was also tested
by transient transgenesis. When both motifs (GGGTCA) of the site
are mutated within the 111 kb-Myf5 enhancer, no signiﬁcant
differences in b-galactosidase activity were detected (Fig.S6),
compared with the non-mutated construct (Fig.S2), at the 25–35
somite stages examined. We were interested in possible early left/
right differences since COUP-TFII has been implicated in retinoic
acid mediated control of somite symmetry in chick and mouse
embryos (Vilhais-Neto et al., 2010). However, mutant transgene
expression remained similar to wild type in left and right sides of
embryos (Fig. S6A, B).Discussion
We have examined three conserved sequences (Maak et al.,
2006) in the -140/100 kb genomic region 50 of the Myf5 gene
and show that these mainly direct activity to the central/hypaxial
domain of the myotome in the embryo. The 111 kb-Myf5
enhancer alone shows this activity, which corresponds to the
Fig. 3. Pax3 and Six1/4 proteins interact in vivo with the 111 kb-Myf5 enhancer and 111 kb-Myf5e nhancer activation is affected in Pax3GFP/GFP mutant embryos. (A)
ChIP experiments were carried out with anti-Pax3, anti-Six1 and anti-Six4 antibodies to immunoprecipitate sonicated chromatin, prepared from the trunk of E10.5 wild-
type embryos. The histogram represents fold change in occupancy of the 111 kb-Myf5 enhancer versus two different negative control regions (which do not bind Pax3
and Six proteins) located, respectively, at 257.5 kb (dark grey) and 55.2 kb upstream (light grey) of theMyf5 gene and already used by Bajard et al. (2006) and Giordani
et al. (2007).Results presented are the average of 7 (Pax3), 3 (Six1) and 4(Six4) different ChIPs, with at least 3 different chromatin preparations. Control ChIP with IgGs from
non-immune serum is shown. (B, C) X-Gal staining of embryos at E11.25 showing 111baMyf5nLacZ transgene expression on different Pax3 genetic backgrounds: (B)
Pax3GFP/þ and (C) Pax3GFP/GFP. Expression due to the branchial arch region is marked by an asterisk. Analysis of cryostat sections from caudal-most interlimb somites in
heterozygous Pax3GFP/þ (D, E) or homozygous Pax3GFP/GFP. (F, G) embryos by immunoﬂuorescence with anti-GFP antibodies (D, F) or X-Gal staining on the same sections (E,
G) (black lines in B and C indicate level of sections). NT¼ Neural Tube. X-Gal positive cells in the ventral neural tube, expressing the transgene under the control of a neural
element present in the ba promoter sequence of the construct, are detectable in G (black arrowhead). (H–J) lateral views of X-Gal stained Pax3þ /þ (H), Pax3GFP/þ (I) and
Pax3GFP/GFP (J) embryos at E13.0 show 111baMyf5nLacZ transgene expression. Labelling in trunk and limb musculature and in caudal-most somites, visible in H–I, is
absent in J (black arrowheads).
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Fig. 4. Transient transgenic analysis reveals the importance of Pax3 and Six1/4 binding sites for activity of the 111 kb-Myf5 enhancer. The importance of the Pax3 or Six1/
4 binding sites was tested in vivo in transient transgenic embryos at E10.5, using a wild type 111baMyf5nLacZ construct or the same construct with different
combinations of mutated Pax3 and/or Six1/4 binding sites, already tested in EMSA. Lateral views of representative embryos are shown on the upper part of the panel, and
enlarged views of the interlimb regions of the same embryos are shown below. n indicates the number of embryos obtained with each construct. Mutation of both SixBS1
and 2 (B) results in some reduction of transgene expression. X-Gal staining is consistently lower than with the wild-type construct (A); this is visible at the interlimb level
where nLacZ expression is mainly restricted to the caudal and rostral edges of the somite (B). Individual mutations of Pax3 binding sites show reduced X-Gal staining in the
absence of PBS2 (C) and a strong effect on 111baMyf5nLacZ transgene expression when PaxBS1 is mutated (D). Mutation of both PaxBS1 and 2 (E) completely abolishes
the activity of the 111 kb enhancer. Finally, mutations at the four sites, SixBS1/2 and PaxBS1/2 (F), also abolishes transgene activity. X-Gal staining in the branchial
arches (asterisks) and in the neural tube, due to the sequences present in the baMyf5 proximal region, serve as a positive control.
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the hypaxial lip of the dermomyotome which we had expected to
be directed by conserved sequences in this region, since BAC
deletion analysis had indicated that this depends on a region
between 140/88 kb upstream of theMyf5 gene (Carvajal et al.,
2001). Genetically we had shown that this early hypaxial expres-
sion of Myf5 is Pax3 dependent (Bajard et al., 2006). However if
Pax3 dependence acts through the 111 kb-Myf5 enhancer, other
sequences outside the 130/111 kb region must also be
required. In both transgenic lines that we have analysed, the
111 kb-Myf5 enhancer continues to direct robust expression at
foetal stages (E13/E14), at sites of myogenesis in the trunk,
notably in intercostal and abdominal muscles, as well as in
proximal muscles of the limbs. Myf5 expression, in hypaxial
somites from E10.5 and from the onset of myogenesis in the
limbs, depends on the 145 bp regulatory sequence at 57.5 kb
(Hadchouel et al., 2000). A further sequence in this region also
directs expression to hindlimbs and may complement the action
of the 145 bp-Myf5 enhancer which is more active in the fore-
limbs. We conclude that the activity of the 111 kb-Myf5 enhan-
cer in proximal limb muscles overlaps with that of the 57.5 kb
region. It should be noted that this regulatory 111 kb region is
also implicated in expression ofMyf5 in quiescent satellite cells of
the adult soleus limb muscle (Soleimani et al., 2012). Our
observations at foetal stages are in contrast to the report of
Ribas et al. (2011), of rapid loss of activity after E11.5. Their
ECR111 enhancer lacks 140 nucleotides present at the 30 end of
the 111 kb-Myf5 enhancer, which includes SixBS2. However
deletion of this site does not have a striking effect. It may be a
question of the combination with proximal sequences since we
have included the branchial arch region with the proximal
promoter (1109 bp) whereas the proximal promoter (136 bp)
and the brain regulatory region at 55/54.3 kb (Daubas et al.,
2009) were included with the ECR111 enhancer, or alternatively
there may be differences in the robustness of transgene expres-
sion in the different lines. Analysis of the regulatory region at
111 kb, compared to that of other Myf5 regulatory sequences,
illustrates the complex spatiotemporal regulation of Myf5;
discrete sequences target subdomains of developing skeletal
muscle in the trunk or limbs to control the precise expression of
this myogenic determination gene.We have identiﬁed Pax3-paired domain binding sites in the
111 kb-Myf5 enhancer and show binding of Pax3 both in vitro and
in vivo. Analysis of enhancer expression in Pax3 mutant embryos,
despite the complication of cell death in the absence of Pax3, suggests
that Pax3 lies genetically upstream of 111 kb-Myf5. This is con-
ﬁrmed by mutation of the Pax binding sites which demonstrates
direct control of the enhancer, notably through PaxBS1. Its sequence,
50GTCATGCTTCTATCCTT 30 contains a paired domain consensus
binding site (50 GTCACSST 30; Epstein et al., 1996). There is also a
putative Pax3 homeodomain binding site located 30 of the PaxBS1,
but, as shown by our in vivo mutational analysis, the somitic
activation of the 111 kb-Myf5 enhancer by Pax3 clearly depends
on the paired domain binding sequence. In a recent report on Pax3/7
targets, Soleimani et al. (2012) show that Pax7 has a higher binding
afﬁnity for the homeodomain binding motif which characterises Pax
binding sites, whereas Pax3 preferentially binds to a subset of sites
that include a paired domain. Among sites identiﬁed in their genome-
wide analysis, PaxBS1 is associated with both Pax3 and Pax7 binding.
In the activated myogenic cells from postnatal limb muscle used in
this study, Pax7 is the predominant factor, whereas in the embryo
Pax3 plays a major role (Buckingham and Relaix, 2007). It was
previously shown that ECR111 depends on an M-CAT site that binds
non-tissue speciﬁc TEAD factors (Ribas et al., 2011). Since this site is
adjacent to PaxBS1 and to a sequence which is likely to be in contact
with the –COOH-terminal RED domain of the Pax3 paired domain, we
examined potential interactions between TEAD2 and Pax3 binding in
this region. Mutation of either site did not affect binding of the other
factor, and they can both bind to the same sequence. We also saw no
evidence of co-operativity between the factors when bound to DNA.
In our reticulocyte lysate in vitro system, the presence of excess
TEAD2 appeared to augment Pax3 binding, potentially through a
secondary effect on the stability or binding accessibility of the Pax
protein. It is not clear that this has any in vivo signiﬁcance.
We conclude that both Pax and TEAD factors acting independently
through their respective DNA binding sites are essential for 111 kb-
Myf5 enhancer activity.
We also investigated the potential function of a Nr2f2(COUP-TFII)
site (Cooney et al., 1992) that we show binds this factor in vitro. This
is potentially interesting in the context of the symmetry of Myf5
activation in adjacent somites on either side of the axis, since COUP-
TFII is initially expressed in somites only on the right side of the
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counteracting left signalling. However we did not detect any asym-
metry of transgene activation when this site is mutated, perhaps
because onset of 111 kb-Myf5 enhancer activity (from E9.25) occurs
after the early phase of somitogenesis (from E8.0). This site is also a
potential target for thyroid hormone receptor, known to intervene in
the regulation of the mouseMyoD (Muscat et al., 1994) andmyogenin
(Downes et al., 1993) genes, where it has been proposed that COUP-
TFII functions as an antagonist of thyroid hormone receptor binding,
thus repressing activation of these myogenic regulatory genes
(Muscat et al., 1995). Mutation of the Nr2f2(COUP-TFII) binding site
did not affect 111 kb-Myf5 enhancer activity at the embryonic
stages examined. However this thyroid hormone response (TRE)
element may play a role in adult muscles since the Myf5 enhancer
is active in quiescent satellite cells (Soleimani et al., 2012) which
respond to thyroid hormone (Cassar-Malek et al., 1999).
In addition to PaxBS1/2, we also showed that the SixBS1/2, which
bind Six1 and Six4 in vivo, as well as in vitro, have some effect on
111 kb-Myf5 enhancer activity. However this is much less striking
than the requirements for PaxBS1, or indeed PaxBS2. Six1/4 like Pax3/
7 factors are upstream regulators of myogenesis (see Buckingham
and Relaix, 2007) and, in the double Six1/Six4 mutant, myogenic
progenitor cells in the somite and limbs are affected (Grifone et al.,
2005). We had previously shown that activity of the enhancer at
57.5 kb, that directs expression of Myf5 in the hypaxial somite and
limbs, depends on a Six site (Giordani et al., 2007), as well as
requiring direct activation by Pax3 (Bajard et al., 2006). In the case
of this enhancer, Pax and Six binding sites are within a turn of the
DNA helix (about 11 bp), whereas in the 111 kb-Myf5 enhancer the
two Six sites are more distant from PaxBS1 and 2, and the effect of
mutating the sites is less striking. However in both Myf5 enhancers,
Pax is necessary for activity which is diminished in the absence of Six.
The identiﬁcation of Pax and Six as direct regulators of the 111 kb-
Myf5 enhancer, reported here, therefore underlines the importance of
the Pax/Six regulatory network in different aspects of the spatiotem-
poral expression of the Myf5 myogenic determination gene during
skeletal muscle formation in the embryo.Acknowledgements
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